S-3. Public Comment

HHSC reviews drugs meeting the rule criteria and publishes the resulting list as the draft SDL. HHSC welcomes comments from stakeholders using the Specialty Drug Submission Spreadsheet. Stakeholders have 15 business days from publication of the draft document to propose additions to or removals from the draft SDL:

• Requests received outside the 15-business-day review period are kept and reviewed during the following biannual review
• HHSC provides an initial acknowledgment and additional follow-up on whether the proposal was accepted or denied

HHSC publishes a final SDL, incorporating approved public comment, biannually in March and Sept.